Roivant Sciences Ltd. and its subsidiary Priovant Therapeutics still have big plans for the dual TYK2/JAK1 inhibitor brepocitinib, but those plans no longer include further development in systemic lupus erythematosus. The firm said the drug, partnered with Pfizer Inc., showed a strong responder rate but also a high placebo response in a Phase II study, leaving brepocitinib difficult to evaluate in an indication Roivant was only mildly enthused about, CEO Matt Gline said in an interview.
Roivant Won’t Continue With Brepocitinib In Lupus After Phase II Failure
The company wants to focus efforts with the TYK2/JAK1 inhibitor in orphan rheumatology indications like dermatomyositis where current treatment options are inadequate.
